相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Assessment of laboratory assays to measure rivaroxaban - an oral, direct factor Xa inhibitor
Meyer Michel Samama et al.
THROMBOSIS AND HAEMOSTASIS (2010)
Safety, pharmacokinetics and pharmacodynamics of single/multiple doses of the oral, direct Factor Xa inhibitor rivaroxaban in healthy Chinese subjects
Xia Zhao et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2009)
Comparative Pharmacodynamics and Pharmacokinetics of Oral Direct Thrombin and Factor Xa Inhibitors in Development
Bengt I. Eriksson et al.
CLINICAL PHARMACOKINETICS (2009)
A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein-DVT Dose-Ranging Study
Harry R. Buller et al.
BLOOD (2008)
Population pharmacokinetics and pharmacodynamics of rivaroxaban - An oral, direct factor Xa inhibitor in patients undergoing major orthopaedic surgery
Wolfgang Mueck et al.
CLINICAL PHARMACOKINETICS (2008)
Dose-escalation study of the pharmacokinetics and pharmacodynamics of rivaroxaban in healthy elderly subjects
Dagmar Kubitza et al.
CURRENT MEDICAL RESEARCH AND OPINION (2008)
Monitoring direct FXa-inhibitors and fondaparinux by Prothrombinase-induced Clotting Time (PiCT): Relation to FXa-activity and influence of assay modifications
Sebastian Harder et al.
THROMBOSIS RESEARCH (2008)
Effects of the oral, direct factor Xa inhibitor rivaroxaban on platelet-induced thrombin generation and prothrombinase activity
Jochen Graff et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2007)
In vitro inhibition of thrombin generation, after tissue factor pathway activation, by the oral, direct factor Xa inhibitor rivaroxaban
G. T. Gerotziafas et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2007)
Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939 - an oral, direct Factor Xa inhibitor - after multiple dosing in healthy male subjects
D Kubitza et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2005)
Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor
D Kubitza et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2005)
In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939 -: an oral, direct Factor Xa inhibitor
E Perzborn et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2005)